Matches in DBpedia 2016-04 for { ?s ?p "Manuel Elkin Patarroyo (born November 3, 1946) is a Colombian Professor of Pathology and Immunology who made the world's first attempt to create a synthetic vaccine against a parasite called the protozoa Plasmodium falciparum that causes severe malaria, a disease transmitted by mosquitoes that affects millions of people and is one of the leading causes of death (~1.5 million people per year) in tropical and subtropical regions, including parts of the Americas, Asia, and Africa.The vaccine candidate, first developed in 1987 in Colombia, was evaluated in clinical trials carried out by the WHO in Gambia, Tanzania and Thailand, and had mixed results. In 2009, a comprehensive Cochrane review assessed the SPf66 as being not efficacious in Africa and Asia, and as having a low but statistically significant efficacy of 28% in South America. Today, after more than 33 years of research, there is still however no licensed malaria vaccine. Researchers and vaccine developers have been working on many approaches to bring forward the availability of a malaria vaccine.\" More research and clinical trials are required for a universal vaccine to be implemented."@en }
Showing triples 1 to 1 of
1
with 100 triples per page.
- Manuel_Elkin_Patarroyo abstract "Manuel Elkin Patarroyo (born November 3, 1946) is a Colombian Professor of Pathology and Immunology who made the world's first attempt to create a synthetic vaccine against a parasite called the protozoa Plasmodium falciparum that causes severe malaria, a disease transmitted by mosquitoes that affects millions of people and is one of the leading causes of death (~1.5 million people per year) in tropical and subtropical regions, including parts of the Americas, Asia, and Africa.The vaccine candidate, first developed in 1987 in Colombia, was evaluated in clinical trials carried out by the WHO in Gambia, Tanzania and Thailand, and had mixed results. In 2009, a comprehensive Cochrane review assessed the SPf66 as being not efficacious in Africa and Asia, and as having a low but statistically significant efficacy of 28% in South America. Today, after more than 33 years of research, there is still however no licensed malaria vaccine. Researchers and vaccine developers have been working on many approaches to bring forward the availability of a malaria vaccine.\" More research and clinical trials are required for a universal vaccine to be implemented.".